ENAMINE
13.12.2023 09:01:36 CET | Business Wire | Press release
The two leading experts in the exploration of ultra-large make-on-demand chemical spaces join forces to spark a new era of drug discovery. Chief research chemicals provider Enamine and software innovator BioSolveIT have officially joined forces to establish the world's most comprehensive chemical space exploration platform. This strategic partnership is destined to reshape the landscape of chemical research, providing unprecedented benefits for drug hunters worldwide: more compounds to choose from, at the most competitive prices, with maximum speed of delivery and reliability. This new and exclusive alliance is based on and aims to supersede the already enormously successful REAL concept that has transformed and accelerated the hunt for new chemical entities in the fight against human diseases, in crop protection, and animal health, by providing access to billions of compounds on demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211141956/en/
The alliance between BioSolveIT and Enamine will be game-changing in the pursuit of innovation within the pharma industry. Leveraging their respective strengths and expertise, the two companies are poised to create a synergy that will vastly expand today’s possibilities in discovering new chemical entities. The exclusive partnership will cover all aspects of chemical space exploration, from making larger and larger portions of chemical space accessible through trailblazing software solutions for ligand and structure-based exploration, and ultimately to synthesis at unprecedented success rates and delivery times.
Key advantages awaiting researchers worldwide:
- Exponential growth of novel IP: The combined expertise will unlock novel chemical matter at an unprecedented rate, providing trillions of new opportunities for drug discovery and development.
- Tailored chemical spaces: BioSolveIT’s unique algorithms coupled with Enamine’s vast chemistry expertise will enable clients to dive much deeper into chemical spaces, including bespoke spaces customized for clients’ needs.
- Massive savings along the DMTA cycle: Discovery of novel chemical entities within minutes on standard computers, compound sourcing up to 90% less expensive, and well over 80% successful syntheses, all within at most 3-4 weeks.
Professor Dr. Andrey Tolmachov, Founder and CEO at Enamine, says: "Over the past few years, BioSolveIT has taken virtual screening to a whole new level. I am very impressed by their algorithms that handle billions of virtual compounds as if they were only a few hundred thousand. Their chemical space exploration techniques and our make-on-demand offering are a perfect match.” Tolmachov continues: “Researchers can cherry-pick exactly those molecules that are interesting to them, and we successfully synthesize and ship these worldwide in record time.”
Dr. Christian Lemmen, CEO of BioSolveIT, appraises: "Enamine is really an outstanding supplier in this field. Whomever you ask, Enamine is their first choice when it comes to compound sourcing with the highest reliability at unprecedented speed. During these tough times, this is even more admirable.” Lemmen explains further: “Together, we have only just begun to redefine drug discovery via chemical space exploration. Our shared knowledge will help researchers and, ultimately, patients around the world.”
About BioSolveIT GmbH
BioSolveIT is a globally acting medicinal chemistry informatics and services company. It is renowned for its superior software solutions for affinity estimation, structure-based design, ligand-based design, high-throughput virtual screening, library design, and analysis. Their fast, visual, and easy computational technologies help innovate pharmaceutical research with a proven track record in almost all big pharma companies, amongst them AstraZeneca, F. A. Hoffmann-LaRoche, BASF, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, and many others. BioSolveIT’s infiniSee platform rapidly became an industry standard for navigation in molecular chemical spaces of unparalleled sizes. BioSolveIT software is loaded with award-winning algorithms. Profiting from radically simple user interfaces, the company’s applications address medicinal chemists and computational experts alike.
BioSolveIT is headquartered in Sankt Augustin, Germany. Support and sales offices are located in Boston, MA, and San Diego, CA, USA. Distribution partners maintain offices in Japan, China, South Korea, and India.
About Enamine Ltd.
Headquartered in Kyiv, Ukraine, Enamine is a scientifically driven integrated discovery Contract Research Organization with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4M in stock) and building blocks (300K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. Enamine has developed the largest offering of make-on-demand compounds that includes trillions of Enamine REAL molecules and over a billion of Enamine MADE building blocks. The company’s unique knowledge-based approach allows for fast and inexpensive delivery of novel entities from the above make-on-demand chemical space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231211141956/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom